Book a Meeting
Creative Biolabs - ADCC+ Antibody

Anti-CD30 Antibody, ADCC Enchanced (BioBet-CB-059LX) (CAT#: BioBet-CB-059LX) Datasheet

Target
CD30
Isotype
IgG
Description
Anti-CD30 Antibody, ADCC Enchanced (BioBet-CB-059LX) is a glycosylation-modified anti-CD30 therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD30 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD30
Full Name
TNF receptor superfamily member 8
Background
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2008]
Alternative Names
CD30; Ki-1; D1S166E
Gene ID
943
UniProt ID
P28908
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-CB-059LX
Host
Human
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human CD30 (AFM13) Antibody is derived from clone AFM13, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the CD30, and it is intended for the research of Peripheral T Cell Lymphoma.
Antibody Indication
Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

Related Products

Anti-CD30 Antibody, Non-Fucosylated (BioBet-472ZP) (CAT#: BioBet-472ZP)
Anti-CD30 Antibody, Half-Life Extended (AES-0622-ZP1036) (CAT#: AES-0622-ZP1036)
Anti-CD30 Antibody, Non-Fucosylated (BioBet-1749ZP) (CAT#: BioBet-1749ZP)
Anti-CD30 Antibody, Non-Fucosylated (BioBet-1748ZP) (CAT#: BioBet-1748ZP)
Anti-CD30 Antibody, Non-Fucosylated (AC10) (CAT#: BioBet-1390ZP)
Anti-CD30 Antibody, Non-Fucosylated (XmAb 2513) (CAT#: BioBet-1389ZP)
Anti-CD30 Antibody, Highly Galactosylated (BioBet-GA-036ZP) (CAT#: BioBet-GA-036ZP)
Anti-CD30 Antibody, On-Target (AES-0622-ZP708) (CAT#: AES-0622-ZP708)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.